Repligen to Attend Three Investor Conferences in September
PorAinvest
viernes, 22 de agosto de 2025, 7:32 am ET1 min de lectura
RGEN--
At the Wells Fargo Healthcare Conference, scheduled from September 3 to 5 in Boston, CEO Olivier Loeillot will join an analyst discussion on September 4 at 8:00 a.m. ET. The Deutsche Bank Healthcare Summit, taking place on September 10 and 11 in New York City, will see CFO Jason Garland participate in 1x1 meetings on September 10. Finally, at the Bank of America Global Healthcare Conference, from September 23 to 25 in London, CEO Olivier Loeillot will participate in an analyst discussion on September 25 at 6:35 a.m. ET. Live webcasts of these events will be available on Repligen’s Investor Relations website.
Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems. These technologies aim to enhance the efficiency of manufacturing biological drugs, primarily for biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. The company's headquarters are located in Waltham, Massachusetts, with manufacturing sites across several countries, including the United States, Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information about Repligen Corporation, visit their website at [Repligen Corporation](https://www.repligen.com) and follow them on LinkedIn.
References:
[1] https://www.stocktitan.net/news/RGEN/repligen-corporation-to-present-at-upcoming-september-jzxm1p0l9340.html
[2] https://www.biospace.com/press-releases/restart-life-sciences-provides-corporate-update-on-strategy-and-growth-initiatives
Repligen Corporation, a life sciences company, announced its participation in three investor conferences. Olivier Loeillot, CEO, will present at the Wells Fargo Healthcare Conference on September 4 and the Bank of America Global Healthcare Conference on September 25. Jason Garland, CFO, will participate in 1x1 meetings at the Deutsche Bank Healthcare Summit on September 10. Live webcasts of the presentations will be available on Repligen's Investor Relations website.
Repligen Corporation (NASDAQ: RGEN), a leading bioprocessing technology company in life sciences, has announced its participation in three significant investor conferences in September 2025. The company will be presenting at the Wells Fargo Healthcare Conference, the Deutsche Bank Healthcare Summit, and the Bank of America Global Healthcare Conference. Live webcasts of the presentations will be available on Repligen's Investor Relations website.At the Wells Fargo Healthcare Conference, scheduled from September 3 to 5 in Boston, CEO Olivier Loeillot will join an analyst discussion on September 4 at 8:00 a.m. ET. The Deutsche Bank Healthcare Summit, taking place on September 10 and 11 in New York City, will see CFO Jason Garland participate in 1x1 meetings on September 10. Finally, at the Bank of America Global Healthcare Conference, from September 23 to 25 in London, CEO Olivier Loeillot will participate in an analyst discussion on September 25 at 6:35 a.m. ET. Live webcasts of these events will be available on Repligen’s Investor Relations website.
Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems. These technologies aim to enhance the efficiency of manufacturing biological drugs, primarily for biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. The company's headquarters are located in Waltham, Massachusetts, with manufacturing sites across several countries, including the United States, Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information about Repligen Corporation, visit their website at [Repligen Corporation](https://www.repligen.com) and follow them on LinkedIn.
References:
[1] https://www.stocktitan.net/news/RGEN/repligen-corporation-to-present-at-upcoming-september-jzxm1p0l9340.html
[2] https://www.biospace.com/press-releases/restart-life-sciences-provides-corporate-update-on-strategy-and-growth-initiatives
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios